1. Search Result
Search Result
Results for "

prostaglandin COX

" in MedChemExpress (MCE) Product Catalog:

106

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

2

Peptides

18

Natural
Products

2

Recombinant Proteins

13

Isotope-Labeled Compounds

6

Antibodies

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14654
    Aspirin
    30+ Cited Publications

    Acetylsalicylic acid; ASA

    Environmental Pollutants Autophagy NF-κB Apoptosis COX Mitophagy Virus Protease Caspase p38 MAPK Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin
  • HY-N6966
    Ethyl Caffeate
    2 Publications Verification

    NF-κB NO Synthase COX PGE synthase Inflammation/Immunology Cancer
    Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa. Ethyl caffeate suppresses NF-κB activation and its downstream inflammatory mediators, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2) in vitro or in mouse skin .
    Ethyl Caffeate
  • HY-13913
    NS-398
    15+ Cited Publications

    COX Inflammation/Immunology Cancer
    NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (COX-2) activity, with an IC50 of 3.8 μM, and has no effect on COX-1 at 100 μM.
    NS-398
  • HY-14654R
    Aspirin (Standard)
    30+ Cited Publications

    Acetylsalicylic acid(Standard); ASA (Standard)

    Reference Standards COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Standard) is the analytical standard of Aspirin. This product is intended for research and analytical applications. Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin (Standard)
  • HY-B1153
    Glafenine
    4 Publications Verification

    Glafenin

    COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Metabolic Disease Inflammation/Immunology
    Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine
  • HY-B1452
    Licofelone
    1 Publications Verification

    ML-3000

    COX Lipoxygenase Apoptosis Inflammation/Immunology Cancer
    Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins .
    Licofelone
  • HY-B0531

    COX Phosphodiesterase (PDE) NF-κB NO Synthase Prostaglandin Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
    Triflusal
  • HY-129611

    Apoptosis Inflammation/Immunology Cancer
    Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
    Bromelain
  • HY-124108

    ETYA

    COX Lipoxygenase Orthopoxvirus Potassium Channel DNA/RNA Synthesis Drug Derivative Infection Neurological Disease Inflammation/Immunology Cancer
    Eicosatetraynoic acid (ETYA) is a non-metabolizable analog of Arachidonic acid (HY-109590) and also an inhibitor of the lipoxygenase (LOX)/cyclooxygenase (COX) pathway (ID50 = 8 μM and 4 μM). Eicosatetraynoic acid acts as a suicide substrate to inhibit the production of inflammatory mediators such as leukotrienes and prostaglandins. Eicosatetraynoic acid acts directly on cell membranes and membrane proteins to exert a wide range of effects, including blocking potassium channels, increasing cell membrane fluidity, elevating intracellular calcium levels, inhibiting DNA synthesis in tumor cells, inducing differentiation of certain cells, and specifically inhibiting the assembly and replication of orthopoxviruses. Eicosatetraynoic acid alleviates acute lung injury induced by chemicals such as phosgene .
    Eicosatetraynoic acid
  • HY-B0336
    Pranoprofen
    2 Publications Verification

    COX Apoptosis PGE synthase Inflammation/Immunology Cancer
    Pranoprofen is a non-steroidal anti-inflammatory agent (NSAID) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit COX-1 and COX-2 enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis .
    Pranoprofen
  • HY-B0641

    4-Biphenylacetic acid

    COX Inflammation/Immunology
    Felbinac is a metabolite of fenbufen, an orally active nonsteroidal anti-inflammatory agent and a cyclooxygenase (COX) inhibitor with an IC50 of 865.68 nM for COX1 and 976 nM for COX2. Felbinac reduces the production of prostaglandins by inhibiting COX to relieve pain, reduce inflammation and reduce fever. Felbinac can inhibit CHIKV viral activity .
    Felbinac
  • HY-17474
    Parecoxib
    5 Publications Verification

    SC 69124

    COX Infection Neurological Disease Inflammation/Immunology Cancer
    Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib
  • HY-N8469

    COX Inflammation/Immunology
    cis-5-Dodecenoic acid is an inhibitor of COX-I and COX-II with anti-inflammatory activity. cis-5-Dodecenoic acid reduces prostaglandin synthesis by inhibiting COX enzyme activity and is involved in the fatty acid -β oxidative metabolic pathway. The metabolic rate of cis-5-Dodecenoic acid is significantly lower than that of saturated fatty acids. cis-5-Dodecenoic acid can be used in the research of anti-inflammation, fatty acid metabolism mechanisms and related physiological and pathological processes .
    cis-5-Dodecenoic acid
  • HY-N12586

    ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease Infection Neurological Disease Cancer
    Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC50=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .
    Pheophytin a
  • HY-D0053

    6-Carboxy-X-rhodamine

    Fluorescent Dye Others
    6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .
    6-ROX
  • HY-10439

    PGE synthase Inflammation/Immunology
    HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .
    HPGDS inhibitor 1
  • HY-W012817

    Environmental Pollutants COX Inflammation/Immunology
    Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .
    Methylhydroquinone
  • HY-14654S1

    Acetylsalicylic acid-d4; ASA-d4

    Isotope-Labeled Compounds COX Autophagy Mitophagy Virus Protease NF-κB Apoptosis Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin-d4 is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin-d4
  • HY-17357

    AHR 9434; AL 6515

    COX Prostaglandin Receptor Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Nepafenac (AHR 9434; AL 6515), a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries .
    Nepafenac
  • HY-E70127

    Brasan; Dasen

    Ser/Thr Protease COX Bacterial Prostaglandin Receptor Interleukin Related Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
    Serratiopeptidase (Brasan; Dasen) is an orally active zinc-containing metalloprotease belonging to the serralysin family. Serratiopeptidase reduces the release of inflammatory mediators such as prostaglandins, thromboxanes and interleukins by inhibiting COX, thereby relieving pain, swelling and redness. Serratiopeptidase exhibits antibiofilm, mucolytic and wound-healing activities. As a serine protease, Serratiopeptidase has the ability to dissolve blood clots, fibrin and atherosclerotic plaques. Serratiopeptidase degrades amyloid fibrils and has potential anti-Alzheimer's effects. Serratiopeptidase shows cytotoxicity against colon cancer cells .
    Serratiopeptidase
  • HY-108259

    PGE synthase Inflammation/Immunology
    HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS .
    HQL-79
  • HY-14654S

    Acetylsalicylic acid-d3; ASA-d3

    Isotope-Labeled Compounds COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin-d3 is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin-d3
  • HY-N2106
    Dehydroevodiamine
    2 Publications Verification

    NF-κB COX PGE synthase NO Synthase Inflammation/Immunology
    Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes . Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells .
    Dehydroevodiamine
  • HY-106579
    Tiaprofenic acid
    1 Publications Verification

    COX Inflammation/Immunology
    Tiaprofenic acid is an orally active nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic potency. Tiaprofenic acid inhibits prostaglandin synthesis by suppressing cyclo-oxygenase (COX). Tiaprofenic acid can be used in the treatment of rheumatic diseases .
    Tiaprofenic acid
  • HY-113331
    Thromboxane B2
    1 Publications Verification

    Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation. Thromboxane B2 is a biological inactive product and circulating catabolite of thromboxane A2. Thromboxane B2 levels in peripheral venous blood and coronary sinus blood can be used as a diagnostic marker for angina. Thromboxane B2 level in serum is also associated with inhibition of COX-1 activity inhibition in platelets. Thromboxane B2 is a major product of prostaglandin endoperoxide metabolism. Thromboxane B2 produces dose-related decreases in airflow rate, tidal volume and dynamic lung compliance, whilst simultaneously increasing pulmonary airway resistance in dog model. Thromboxane B2 appears to be a naturally occurring bronchoactive metabolite in the bioconversion of arachidonic acid .
    Thromboxane B2
  • HY-139589

    ISC-27864; GRC-27864

    PGE synthase COX Collagen Neurological Disease Inflammation/Immunology
    Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH2 to prostaglandin PGE2, thereby inhibiting inflammation-related PGE2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE2 release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC50s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .
    Zaloglanstat
  • HY-165131

    Delta-7-avenasterol

    Prostaglandin Receptor COX Inflammation/Immunology
    Δ7-Avenasterol (Delta-7-avenasterol) is a phytosterol that binds to prostaglandin E2 receptor (prostaglandin E2 receptor) and cyclooxygenase-2 (COX-2). Δ7-Avenasterol is applicable to research related to gastric ulcer, anti-inflammation and antioxidation .
    Δ7-Avenasterol
  • HY-103387
    DuP-697
    1 Publications Verification

    COX Apoptosis Inflammation/Immunology Cancer
    DuP-697 is a member of the vicinal diaryl heterocycles and a potent, irreversible, selective and orally active COX-2 inhibitor (IC50 of 10 nM and 800 nM for human COX-2 and COX-1, respectively). DuP-697 exerts antiproliferative (IC50 of 42.8 nM), antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. DuP-697 inhibits prostaglandin synthesis and has anti-inflammatory, anticancer and antipyretic effects .
    DuP-697
  • HY-N0074
    Byakangelicol
    1 Publications Verification

    COX Inflammation/Immunology
    Byakangelicol, isolated from Angelica dahurica, inhibits interleukin-1beta (IL-1beta) -induced prostaglandin E2 (PGE2) release in A549 cells mediated by suppression of cyclooxygenase-2 (COX-2) expression and the activity of COX-2 enzyme. Byakangelicol has therapeutic potential as an anti-inflammatory agent on airway inflammation .
    Byakangelicol
  • HY-17474A
    Parecoxib Sodium
    5 Publications Verification

    SC 69124A

    COX Infection Neurological Disease Inflammation/Immunology Cancer
    Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib Sodium
  • HY-B1153A
    Glafenine hydrochloride
    4 Publications Verification

    Glafenin hydrochloride

    COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Metabolic Disease Inflammation/Immunology
    Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine hydrochloride
  • HY-133159

    (-)-Resolvin E2

    Endogenous Metabolite Leukotriene Receptor Chemerin Receptor COX Lipoxygenase Neurological Disease Inflammation/Immunology
    Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E2, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors . Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions .
    Resolvin E2
  • HY-139578

    COX Inflammation/Immunology
    Ocarocoxib is a potent cyclooxygenase-2 (COX-2) inhibitor (IC50: 1.4 μM). Ocarocoxib inhibits COX to block the production of prostaglandins, thus exerting an anti-inflammatory effect. Ocarocoxib has potential in the study of inflammation and related diseases .
    Ocarocoxib
  • HY-E70229

    COX-1

    Endogenous Metabolite Metabolic Disease
    Cyclooxygenase 1, sheep (COX-1) is a 71 kDa membrane bound protein predominantly present in endoplasmic reticulum. Cyclooxygenase 1 has three domains, the epidermal growth factor (EGF) like domain, enzymatic and membrane binding domain. Cyclooxygenase 1 mediates prostaglandin synthesis and is modulated by anti-inflammatory nonsteroidal drugs .
    Cyclooxygenase 1, sheep
  • HY-B1153R

    Glafenin (Standard)

    COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reference Standards Metabolic Disease Inflammation/Immunology
    Glafenine (Standard) is the analytical standard of Glafenine. This product is intended for research and analytical applications. Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine (Standard)
  • HY-B2121

    6-MNA; Naproxen impurity O

    Drug Metabolite COX Neurological Disease Inflammation/Immunology
    6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E2. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds .
    6-Methoxy-2-naphthoic acid
  • HY-P4406
    Abz-AGLA-Nba
    1 Publications Verification

    Fluorescent Dye Others
    Abz-AGLA-Nba is a fluorogenic substrate for the determination of protease activity. Abz-AGLA-Nba is hydrolyzed to release aminoacyl benzimide (Abz-AGLA) and 2-naphthylaminoacyl (Nba). The product Abz-AGLA produced by this hydrolysis reaction is fluorescent under ultraviolet light and can emit a fluorescent signal .
    Abz-AGLA-Nba
  • HY-17357S

    AHR-9434-d5; AL-6515-d5

    Isotope-Labeled Compounds COX Prostaglandin Receptor Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Nepafenac-d5 (AHR-9434-d5; AL-6515-d5) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
    Nepafenac-d5
  • HY-105024

    Lipoxygenase COX Inflammation/Immunology
    FPL 62064 is a potent 5-lipoxygenase (5-LOX) and COX dual inhibitor, with IC50 values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity .
    FPL 62064
  • HY-113330
    12S-HHT
    1 Publications Verification

    12(S)-HHTrE

    Leukotriene Receptor Endogenous Metabolite Inflammation/Immunology
    12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H2 (PGH2) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity .
    12S-HHT
  • HY-116763

    COX LOX-1
    COX-2/5-LOX-IN-4 (Compound 1) is a dual inhibitor that acts on both COX-2 and 5-LOX, with IC50 values of 0.05 μM for COX-2 and 0.003 μM for 5-LOX. By inhibiting the arachidonic acid metabolism pathway, COX-2/5-LOX-IN-4 reduces the production of prostaglandins and leukotrienes, alleviating inflammatory responses. In a rat ear edema model, intravenous administration (0.01 and 0.1 mg/kg) reduced edema by 41% and 44%, respectively, demonstrating significant anti-inflammatory effects. COX-2/5-LOX-IN-4 shows promise for studying the mechanisms of inflammatory diseases .
    COX-2/5-LOX-IN-4
  • HY-17509
    Deracoxib
    1 Publications Verification

    SC 046; SC 46; SC 59046

    COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas .
    Deracoxib
  • HY-113445

    COX Endogenous Metabolite Endocrinology
    Thromboxane B3 is a prostaglandin analog derived from arachidonic acid (AA) in the cyclooxygenase (COX) metabolic pathway. Thromboxane B3 is generated from arachidonic acid (AA) in platelets and vascular endothelial cells through the catalysis of cyclooxygenase (COX) and thromboxane synthase (TXS). Thromboxane B3 has been reported to be formed by human platelets upon ingestion of eicosapentaenoic acid (C20: 5ω3) .
    Thromboxane B3
  • HY-W747297

    COX Endogenous Metabolite Neurological Disease Inflammation/Immunology
    β-Selinene is a sesquiterpene and is the main active component of the essential oil of red purple hibiscus (Callicarpa macrophylla). β-Selinene exhibits significant related antioxidant activity, anti-inflammatory activity, and antipyretic analgesic activity. β-Selinene may exert antioxidant effects by directly scavenging free radicals (DPPH, NO, •OH) and chelating pro-oxidative metal ions (Fe²⁺); inhibit cyclooxygenase (COX) activity, reduce prostaglandin (such as PGE₂) synthesis to exert anti-inflammatory effects; regulate the thermoregulatory set point of the hypothalamus and inhibit inflammatory mediators to exert antipyretic and analgesic effects .
    β-Selinene
  • HY-151173

    Xanthine Oxidase Lipoxygenase COX Metabolic Disease Inflammation/Immunology
    XO/COX/LOX-IN-1 is a XO/COX/LOX inhibitor with an IC50 of 3.2 μM against rat XO, 10.83 μM against 5-LOX, 12.67 μM against COX-1, and 8.31 μM against COX-2. XO/COX/LOX-IN-1 binds to the active sites of XO, 5-LOX, COX-1 and COX-2, thereby blocking enzyme activities associated with uric acid, leukotriene, prostaglandin synthesis and inflammatory pathways. XO/COX/LOX-IN-1 can be used in the research of hyperuricemia and inflammation .
    XO/COX/LOX-IN-1
  • HY-17509S

    SC 046-d3; SC 46-d3; SC 59046-d3

    Isotope-Labeled Compounds COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib-d3 (SC 046-d3; SC 59046-d3) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
    Deracoxib-d3
  • HY-118816

    11-epi PGF2α-EA; 11β-PGF2α-EA; 11β-Prostamide F2α

    Drug Metabolite Metabolic Disease
    11β-Prostaglandin F2α ethanolamide (11β-PGF2α-EA) is the theoretical hepatic metabolite of PGD2-EA, produced during COX-2 metabolism of the endogenous cannabinoid AEA which is found in brain, liver, and other mammalian tissues.1 AEA can be used directly by COX-2 and specific PG synthase to produce ethanolamide congeners of the classical PGs. PGD2-EA is formed in activated RAW 264.7 cells treated with AEA.
    11β-Prostaglandin F2α
  • HY-N6966A

    Others Inflammation/Immunology
    Ethyl trans-caffeate is the trans form of Ethyl Caffeate (HY-N6966). Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa. Ethyl caffeate suppresses NF-κB activation and its downstream inflammatory mediators, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2) in vitro or in mouse skin .
    Ethyl trans-caffeate
  • HY-169430

    PGE synthase
    AGU654 (Compound 44) is a selective mPGES-1 inhibitor with an IC50 of 2.9 nM against mPGES-1. AGU654 inhibits mPGES-1 to block the pathway converting arachidonic acid into prostaglandin E2 (PGE2) by COX-1/2, thereby alleviating inflammatory responses, pain, and fever. In activated human monocyte-derived macrophages and human whole blood models, AGU654 selectively suppresses bacterial exotoxin-induced PGE2 production while preserving the production of other prostaglandins. In guinea pig models, AGU654 significantly alleviates fever, inflammation, and inflammatory pain, exhibiting excellent anti-inflammatory, analgesic, and antipyretic effects. AGU654 holds promise as a strategy for studying inflammatory diseases and pain .
    AGU654
  • HY-P4406A

    Fluorescent Dye Others
    Abz-AGLA-Nba TFA is a fluorogenic substrate for the determination of protease activity. Abz-AGLA-Nba TFA is hydrolyzed to release aminoacyl benzimide (Abz-AGLA) and 2-naphthylaminoacyl (Nba). The product Abz-AGLA produced by this hydrolysis reaction is fluorescent under ultraviolet light and can emit a fluorescent signal .
    Abz-AGLA-Nba TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: